Veliparib (ABT-888), an Oral PARP Inhibitor, and VX-970, an ATR Inhibitor, in Combination With Cisplatin in People With Refractory Solid Tumors

NCT02723864 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

53

Enrollment

NIH

Sponsor class

Conditions

Neoplasms

Interventions

DRUG: Veliparib + VX-970 + Cisplatin

Sponsor

National Cancer Institute (NCI)